相关实验视频

Updated: Jul 1, 2025

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

奥塞塔米维尔增强了食道状癌高SPNS1的5-FU敏感性

Xin Yang¹, Ye Jiao¹, Yingying Zhang¹

¹Translational Medicine Research Center, Department of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research of Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi 030001, China; Key Laboratory of Cellular Physiology, Shanxi Medical University, Ministry of Education, China; Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|March 9, 2024

概括

脂转运体1 (SPNS1) 通过上调NEU1.1,促进食道状细胞癌 (ESCC) 的进展. 向SPNS1可能会提高ESCC患者的化疗敏感性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

脂转运体1 (SPNS1) 被确定为食道状细胞癌 (ESCC) 中的一个关键差异表达基因 (DEG).
增加SPNS1表达与ESCC患者的预后较差相关.
在ESCC中SPNS1的确切作用和分子机制尚未完全阐明.

研究的目的:

研究SPNS1在ESCC进展中的功能作用.
探索SPNS1影响ESCC的潜在分子机制.
评估SPNS1作为ESCC治疗的治疗点的潜力及其对化疗敏感性的影响.

主要方法:

来自临床ESCC队列的转录和蛋白质组数据的分析.
在体外实验涉及ESCC细胞系中SPNS1的淘汰和过度表达.
细胞增殖,迁移,入侵和细胞亡的评估.
调查SPNS1和NEU1表达之间的关系.
在体内和体外使用欧塞塔米维尔酸盐 (OP),一种NEU1抑制剂的研究.

主要成果:

与正常组织相比,ESCC组织中的SPNS1表达显著高于正常组织,并且与预后不佳有关.
抑制SPNS1抑制ESCC细胞的增殖,迁移和入侵,同时促进细胞亡.
过度表达SPNS1对ESCC细胞行为有相反的影响.
抑制SPNS1会增加ESCC细胞对5-甲 (5-FU) 的敏感性.
NEU1被确定为由SPNS1调节的下游基因,并且与SPNS1表达正相关.
奥塞塔米维尔酸盐 (OP) 逆转了高SPNS1表达对5-FU耐药性,迁移和增殖的影响.

结论:

通过调节NEU1表达,SPNS1促进了ESCC的进展.
在ESCC中,SPNS1影响化疗敏感性.
针对SPNS1或NEU1为ESCC提供了一个潜在的治疗策略.

关键词:

药物敏感性药物敏感性在 ESCC ESCC 的位置上.欧盟国家1 这就是SPNS1的意义.幸存的生存方式治疗目标治疗目标

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...